Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase).

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Journal of Steroid Biochemistry and Molecular Biology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 7918112
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative studies on the effects of aminoglutethimide on hamster and rat adrenal cortex.

  1992cited by this paper
• 4-pregnene-3-one-20 beta-carboxaldehyde: a potent inhibitor of 17 alpha-hydroxylase/C17,20-lyase and of 5 alpha-reductase.

  1992cited by this paper
• Effects of stress on adrenal steroidogenesis blockade by aminoglutethimide.

  1992cited by this paper
• Comparative effects of chronic administration of the non-steroidal antiandrogens flutamide and Casodex on the reproductive system of the adult male rat.

  1991cited by this paper
• The effect of the aromatase inhibitor, rogletimide (pyridoglutethimide), on guinea pig adrenal cell steroidogenesis and placental microsomal aromatase activity: comparison with aminoglutethimide and CGS 16949A.

  1991cited by this paper
• Stress and the endocrine hypothalamus-pituitary-testis system: a review.

  1991cited by this paper
• Inhibition of the pituitary-gonadal axis in nude male mice by continuous administration of LHRH agonists and antagonists.

  1990cited by this paper
• A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.

  1989cited by this paper
• 17 beta-(cyclopropylamino)-androst-5-en-3 beta-ol, a selective mechanism-based inhibitor of cytochrome P450(17 alpha) (steroid 17 alpha-hydroxylase/C17-20 lyase).

  1989cited by this paper
• Ketoconazole as primary treatment of prostatic cancer.

  1988cited by this paper
• Hepatic reactions associated with ketoconazole in the United Kingdom.

  1987cited by this paper
• Inhibition of testosterone production with ketoconazole alone and in combination with a gonadotropin releasing hormone analogue in the rat.

  1986cited by this paper
• Effect of ketoconazole (an imidazole antimycotic agent) and other inhibitors of steroidogenesis on cytochrome P450-catalyzed reactions.

  1986cited by this paper
• Ketoconazole therapy in advanced prostatic cancer.

  1984cited by this paper
• The effects of ketoconazole on testosterone production and normal and malignant androgen dependent tissues of the adult rat.

  1984cited by this paper
• Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes.

  1983cited by this paper
• Fluctuations in plasma testosterone levels in adult male rats and mice.

  1973cited by this paper

• Approved Steroidal Drugs (2000-2025): A Medicinal Chemistry Perspective.

  2026cites this paper
• Emerging therapies to overcome antiandrogen resistance and beyond in lethal prostate cancer.

  2025cites this paper
• Fine structural design of 3βHSD1 inhibitors for prostate cancer therapy

  2025cites this paper
• Real-World Outcomes of Upfront Abiraterone in Metastatic Castration-Sensitive Prostate Cancer Patients at a Tertiary Care Hospital

  2025cites this paper
• Semisynthesis of Forsyshiyanine A and a Derivative with Significant Anti-Pancreatic Cancer Activity

  2025cites this paper
• Abiraterone and Galeterone, Powerful Tools Against Prostate Cancer: Present and Perspective

  2024cites this paper
• PROTACs targeting androgen receptor signaling: potential therapeutic agents for castration-resistant prostate cancer.

  2024cites this paper
• Discovery of novel peptide-dehydroepiandrosterone hybrids inducing endoplasmic reticulum stress with effective in vitro and in vivo anti-melanoma activities.

  2024cites this paper
• The Rapidly Evolving Treatment Landscape of Metastatic Hormone-Sensitive Prostate Cancer

  2024cites this paper
• Dual inhibition of CYP17A1 and HDAC6 by abiraterone-installed hydroxamic acid overcomes temozolomide resistance in glioblastoma through inducing DNA damage and oxidative stress.

  2024cites this paper
• Prospective role of 3βHSD1 in prostate cancer precision medicine

  2023cites this paper
• Pyridine-containing substrate analogs are restricted from accessing the human cytochrome P450 8B1 active site by tryptophan 281

  2023cites this paper
• Preclinical models of prostate cancer — modelling androgen dependency and castration resistance in vitro, ex vivo and in vivo

  2023cites this paper
• RRU_A_303215 87..108

  2022cites this paper
• Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer

  2022cites this paper
• Androgen synthesis inhibition increases behavioural flexibility and mPFC tyrosine hydroxylase in gonadectomized male rats

  2022cites this paper
• Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer

  2022cites this paper
• The clinical efficacy and limitations of dutasteride-regulated abiraterone metabolism in abiraterone-resistant patients: a prospective single-arm clinical trial in Chinese patients

  2022cites this paper
• Inhibiting 3βHSD1 to eliminate the oncogenic effects of progesterone in prostate cancer

  2022cites this paper
• Evolution of Androgen Deprivation Therapy (ADT) and Its New Emerging Modalities in Prostate Cancer: An Update for Practicing Urologists, Clinicians and Medical Providers

  2022cites this paper
• Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation

  2021cites this paper
• Second-generation hormonotherapy in prostate cancer and bone microenvironment.

  2021cites this paper
• Triple-arm androgen blockade for advanced prostate cancer: a review

  2021cites this paper
• An unprecedented endocrine target for ovarian cancer: inhibiting 17β-HSD7 supresses cancer cell proliferation and arrests G2/M cycle.

  2021cites this paper
• Arylacetamide deacetylase as a determinant of the hydrolysis and activation of abiraterone acetate in mice and humans.

  2021cites this paper
• Useful predictors of progression‐free survival for Japanese patients with LATITUDE‐high‐risk metastatic castration‐sensitive prostate cancer who received upfront abiraterone acetate

  2021cites this paper
• Novel alkylaminoethyl derivatives of androstane 3-oximes as anticancer candidates: synthesis and evaluation of cytotoxic effects

  2021cites this paper
• Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States

  2021cites this paper
• The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches.

  2021cites this paper
• Celebrating the 80th anniversary of hormone ablation for prostate cancer.

  2021cites this paper
• Targeting androgen receptor signaling: a historical perspective.

  2021cites this paper
• Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer

  2021cites this paper
• Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review.

  2020cites this paper
• Branched worm-like nanoparticles featured with programmed drug release for synergistic castration-resistant prostate cancer therapy

  2020cites this paper
• Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management and outcome.

  2020cites this paper
• Oral formulation strategies to improve the bioavailability and mitigate the food effect of abiraterone acetate.

  2020cites this paper
• Pharmaceutical drug development: high drug prices and the hidden role of public funding

  2020cites this paper
• Response of prostate cancer to addition of dutasteride after progression on abiraterone

  2020cites this paper
• The role of adrenal derived androgens in castration resistant prostate cancer.

  2020cites this paper
• Treatment gains from the “sandwich method” of abiraterone acetate for men with metastatic prostate cancer: a case report and sharing of our experience

  2020cites this paper
• Pharmacological Modulation of Steroid Activity in Hormone-Dependent Breast and Prostate Cancers: Effect of Some Plant Extract Derivatives

  2020cites this paper
• Management of Bone Metastases

  2019cites this paper
• CYP17A1 and Androgen-Receptor Expression in Prostate Carcinoma Tissues and Cancer Cell Lines

  2019cites this paper
• Increased nuclear factor I/B expression in prostate cancer correlates with AR expression

  2019cites this paper
• Gene Expression Alterations during Development of Castration-Resistant Prostate Cancer Are Detected in Circulating Tumor Cells

  2019cites this paper
• Strategies for the development of highly selective cytochrome P450 inhibitors: Several CYP targets in current research.

  2019cites this paper
• Evolution of the prostate cancer genome towards resistance

  2019cites this paper
• Galeterone and The Next Generation Galeterone Analogs, VNPP414 and VNPP433-3β Exert Potent Therapeutic Effects in Castration-/Drug-Resistant Prostate Cancer Preclinical Models In Vitro and In Vivo

  2019influential citation
• The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels

  2019cites this paper
• Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.

  2019cites this paper
• Interaction of an abiraterone with calf thymus DNA: Investigation with spectroscopic technique and modeling studies

  2019cites this paper
• A drug safety evaluation of abiraterone acetate in the treatment of prostate cancer

  2019cites this paper
• Low-Fat Abiraterone Food Effect Is of Great Consequence.

  2018cites this paper
• Abiraterone Acetate for Cushing Syndrome: Study in a Canine Primary Adrenocortical Cell Culture Model.

  2018cites this paper
• Purchasing silence.

  2018cites this paper
• Synthesis of unprecedented steroidal spiro heterocycles as potential antiproliferative drugs.

  2018cites this paper
• Lineage plasticity-mediated therapy resistance in prostate cancer

  2018cites this paper
• Abiraterone acetate in the treatment of prostate cancer.

  2018cites this paper
• A Study on the Clinical Outcome of Abiraterone Acetate in Castration Resistant Prostate Cancer Patients

  2018cites this paper
• The role of ketoconazole in current prostate cancer care

  2018cites this paper
• Identification, Characterization and High-Performance Liquid Chromatography Quantification for Process-Related Impurities in Abiraterone Acetate Bulk Drug.

  2018cites this paper
• A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers

  2017cites this paper
• Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer

  2017cites this paper
• Effect of the 5α-reductase enzyme inhibitor dutasteride in the brain of intact and parkinsonian mice.

  2017cites this paper
• The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials.

  2017cites this paper
• AWARD NUMBER: W81XWH-14-1-0271 TITLE: Targeting GPR30 in Abiraterone- and MDV3100-Resistant Prostate Cancer PRINCIPAL INVESTIGATOR:

  2017cites this paper
• Synthesis and Characterization of Microbial Metabolites of Abiraterone Acetate and an Evaluation of Their Anticancer Activity against Breast Cancer Cell Line MCF-7

  2017cites this paper
• Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer

  2017cites this paper
• Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.

  2017cites this paper
• Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications

  2017influential citation
• Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial

  2017cites this paper
• Determination of Novel Metabolites of Therapeutic Agents used in the Treatment of Castration-Resistant Prostate Cancer

  2017cites this paper
• AR Signaling in Breast Cancer

  2017cites this paper
• Effects of gonadectomy and inhibition of of androgen synthesis on behavioural flexibility in male rats

  2017cites this paper
• The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer

  2016cites this paper
• In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity

  2016cites this paper
• Abiraterone acetate for metastatic castration‐resistant prostate cancer after docetaxel failure: A randomized, double‐blind, placebo‐controlled phase 3 bridging study

  2016cites this paper
• Association of early PSA decline and time to PSA progression in abiraterone acetate-treated metastatic castration-resistant prostate cancer; a post-hoc analysis of Japanese phase 2 trials

  2016cites this paper
• Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer.

  2016cites this paper
• Resisting resistance: Establishing new treatment options for CRPC patients

  2016cites this paper
• Therapeutic management of bone metastasis in prostate cancer: an update

  2016cites this paper
• Systems Medicine Approaches to Improving Understanding, Treatment, and Clinical Management of Neuroendocrine Prostate Cancer.

  2016cites this paper
• Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts

  2016cites this paper
• Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.

  2016cites this paper
• CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate‐resistant prostate cancer previously treated with docetaxel

  2015cites this paper
• Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment

  2015cites this paper
• Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy

  2015cites this paper
• Emerging drugs for the treatment of bone metastasis

  2015cites this paper
• The development of abiraterone acetate for castration-resistant prostate cancer.

  2015cites this paper
• Rhabdomyolysis-induced acute kidney injury in a cancer patient exposed to denosumab and abiraterone: a case report

  2015cites this paper
• Targeting extra-gonadal androgens in castration-resistant prostate cancer.

  2015cites this paper
• [Pharmacological properties of abiraterone acetate (ZYTIGA® tablet 250 mg), a new drug for the treatment of castration-resistant prostate cancer, and results of its clinical studies].

  2015cites this paper
• The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.

  2015cites this paper
• Battling resistance mechanisms in antihormonal prostate cancer treatment: Novel agents and combinations.

  2015cites this paper
• Molecular foundations for personalized therapy in prostate cancer.

  2015cites this paper
• Understanding the function and mechanisms of intestinal cell kinase in the growth and survival of prostate cancer cells

  2015cites this paper
• Strategies for targeting the androgen receptor axis in prostate cancer.

  2014cites this paper
• Breast cancer: Current and future endocrine therapies

  2014cites this paper
• Steroidogenic factor 1 promotes aggressive growth of castration-resistant prostate cancer cells by stimulating steroid synthesis and cell proliferation.

  2014cites this paper
• Latent hypothyreosis as a clinical biomarker for therapy response under abiraterone acetate therapy.

  2014cites this paper